奥拉帕利在轻中度肝功能不全晚期实体瘤患者中的药代动力学与安全性
本研究为I期开放标签试验,评估奥拉帕利300mg单次给药在肝功能正常、轻度(Child-Pugh A)或中度(Child-Pugh B)肝功能不全晚期实体瘤患者中的药代动力学与安全性。结果显示轻中度肝功能不全患者奥拉帕利暴露量无临床显著变化,安全性特征无差异,无需调整剂量。
要点
- 轻度肝功能不全患者奥拉帕利AUC比值1.15,Cmax比值1.13,与肝功能正常者无临床显著差异。
- 中度肝功能不全患者AUC比值1.08,Cmax比值0.87,暴露量无临床显著变化。
- 轻中度肝功能不全患者无需调整奥拉帕利片剂或胶囊剂量。
核心结论
- 轻中度肝功能不全患者奥拉帕利暴露量较肝功能正常者无临床显著变化,安全性特征无差异,无需调整剂量。
研究设计与样本
- I期开放标签研究,纳入晚期实体瘤患者,分为肝功能正常组、轻度肝功能不全组(Child-Pugh A)和中度肝功能不全组(Child-Pugh B)。
主要发现
- 轻度肝功能不全组相较肝功能正常组的AUC几何最小二乘均值比为1.15(90%CI 0.72, 1.83),Cmax比为1.13(90%CI 0.82, 1.56)。
- 中度肝功能不全组相较肝功能正常组的AUC几何最小二乘均值比为1.08(90%CI 0.66, 1.74),Cmax比为0.87(90%CI 0.63, 1.22)。
- 轻中度肝功能不全患者中未检测到新的安全性信号。
关键数值与推荐
- 轻度肝功能不全(Child-Pugh A)患者奥拉帕利AUC比值1.15(90%CI 0.72, 1.83),Cmax比值1.13(90%CI 0.82, 1.56)。
- 中度肝功能不全(Child-Pugh B)患者奥拉帕利AUC比值1.08(90%CI 0.66, 1.74),Cmax比值0.87(90%CI 0.63, 1.22)。
- 轻中度肝功能不全患者无需调整奥拉帕利片剂或胶囊剂量。
临床怎么用
- 晚期实体瘤合并轻度或中度肝功能不全患者可使用奥拉帕利300mg片剂标准剂量,无需因肝功能调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially hepatically cleared. We investigated the pharmacokinetics (PK) and safety of olaparib in patients with mild or moderate hepatic impairment to provide dosing recommendations. METHODS: This Phase I open-label study assessed the PK, safety and tolerability of single doses of olaparib 300-mg tablets in patients with advanced solid tumours. Patients had normal hepatic function (NHF), or mild (MiHI; Child-Pugh class A) or moderate (MoHI; Child-Pugh class B) hepatic impairment. Blood was collected for PK assessments for 96 hours. Patients could continue taking olaparib 300 mg twice daily for long-term safety assessment. RESULTS: Thirty-one patients received ≥1 dose of olaparib and 30 were included in the PK assessment. Patients with MiHI had an area under the curve geometric least-squares mean (GLSmean) ratio of 1.15 (90% confidence interval 0.72, 1.83) and a GLSmean maximum plasma concentration ratio of 1.13 (0.82, 1.56) vs those with NHF. In patients with MoHI, GLSmean ratio for area under the curve was 1.08 (0.66, 1.74) and for maximum plasma concentration was 0.87 (0.63, 1.22) vs those with NHF. For patients with mild or moderate hepatic impairment, no new safety signals were detected. CONCLUSION: Patients with MiHI or MoHI had no clinically significant changes in exposure to olaparib compared with patients with NHF. The safety profile of olaparib did not differ from a clinically relevant extent between cohorts. No olaparib tablet or capsule dose reductions are required for patients with MiHI or MoHI.
引用
- Rolfo C, Isambert N, Italiano A, et al. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment. Br J Clin Pharmacol. 2020. PMID: 32227355. doi:10.1111/bcp.14283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。